In a decisive move aimed at safeguarding public health and combating drug abuse, the Government of Telangana, through its Drugs Control Administration, has revoked the manufacturing license of Mylan Laboratories Ltd., Unit-7. The cancellation comes in the wake of alarming revelations regarding the unauthorized diversion of the psychotropic substance ‘Alprazolam’ from the company’s licensed premises.
Alprazolam, a potent medication used to treat anxiety and related disorders, is classified as a psychotropic substance under the Narcotic Drugs and Psychotropic Substances Act (NDPS Act). Its misuse and abuse pose grave risks to individuals, including addiction, physical dependence, and a range of adverse effects on both physical and mental health.
The investigation uncovered unauthorized diversions of Alprazolam, with reports indicating the illicit mixing of the drug with toddy, a local alcoholic beverage, leading to serious health consequences. Prohibition & Excise Authorities seized a significant amount of Alprazolam from the company’s premises, underscoring the severity of the situation.
Despite being issued a manufacturing license for Alprazolam, Mylan Laboratories Ltd., Unit-7, failed to notify regulatory authorities about the unauthorized diversions and violations observed during inspections. Such lapses in oversight and control prompted the Drugs Control Administration to take decisive action in the interest of public safety.
Director General V.B. Kamalasan Reddy, IPS, emphasized the need for stringent measures to prevent the unauthorized diversion, pilferage, or theft of narcotic drugs and psychotropic substances by manufacturers. The government pledges to intensify surprise raids on manufacturing units to ensure compliance with regulations and vows to take stringent legal action against violators.
The cancellation of the manufacturing license underscores the government’s commitment to upholding regulatory standards and protecting citizens from the dangers of drug abuse. It sends a clear message to pharmaceutical companies regarding the imperative of strict adherence to regulations and ethical practices in drug manufacturing and distribution.